Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Palau Pharma gives Affectis rights to Cox-2 inhibitor

Executive Summary

In its first deal since a minority position in it was spun out last November, Grupo Uriach's R&D divison Palau Pharma SA (autoimmune and anti-inflammatory medicines) has licensed CNS disease firm Affectis Pharmaceuticals AG exclusive worldwide rights to the Cox-2 inhibitor cimicoxib.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies